Efficacy and safety of degludec U100 versus glargine U300 for the early postoperative management of patients with type 2 diabetes mellitus undergoing coronary artery bypass graft surgery : A non-inferiority randomized trial
© 2022 Diabetes UK..
AIMS: To compare the efficacy and safety of degludec U100 versus glargine U300 for the early postoperative management of patients with type 2 diabetes mellitus (T2D) undergoing coronary artery bypass graft (CABG) surgery.
METHODS: A total of 239 patients were randomly assigned (1:1) to receive a basal-bolus regimen in the early postoperative period using degludec U100 (n = 122) or glargine U300 (n = 117) as basal and glulisine before meals. The primary outcome was mean differences between groups in their daily BG concentrations. The major safety outcome was the occurrence of hypoglycemia.
RESULTS: There were no differences in mean daily BG concentrations (157 vs. 162 mg/dl), mean percentage of readings within target BG of 70-180 mg/dl (74% vs. 73%), daily basal insulin dose (19 vs. 21 units/day), length of stay (median [IQR]: 9 vs. 9 days), or hospital complications (21.3% vs. 21.4%) between treatment groups. There were no differences in the proportion of patients with BG <70 mg/dl (15.6% vs. 23.1%) or <54 mg/dl (1.6% vs. 4.3%) between degludec-100 and glargine-300 groups.
CONCLUSIONS: Treatment with degludec U100 is as effective and safe as glargine U300 for the early postoperative hospital management of patients with T2D undergoing CABG.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Diabetic medicine : a journal of the British Diabetic Association - 40(2023), 1 vom: 30. Jan., Seite e15002 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kuchay, Mohammad Shafi [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.12.2022 Date Revised 14.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/dme.15002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348679912 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348679912 | ||
| 003 | DE-627 | ||
| 005 | 20231226040830.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/dme.15002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1162.xml |
| 035 | |a (DE-627)NLM348679912 | ||
| 035 | |a (NLM)36354383 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kuchay, Mohammad Shafi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of degludec U100 versus glargine U300 for the early postoperative management of patients with type 2 diabetes mellitus undergoing coronary artery bypass graft surgery |b A non-inferiority randomized trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.12.2022 | ||
| 500 | |a Date Revised 14.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Diabetes UK. | ||
| 520 | |a AIMS: To compare the efficacy and safety of degludec U100 versus glargine U300 for the early postoperative management of patients with type 2 diabetes mellitus (T2D) undergoing coronary artery bypass graft (CABG) surgery | ||
| 520 | |a METHODS: A total of 239 patients were randomly assigned (1:1) to receive a basal-bolus regimen in the early postoperative period using degludec U100 (n = 122) or glargine U300 (n = 117) as basal and glulisine before meals. The primary outcome was mean differences between groups in their daily BG concentrations. The major safety outcome was the occurrence of hypoglycemia | ||
| 520 | |a RESULTS: There were no differences in mean daily BG concentrations (157 vs. 162 mg/dl), mean percentage of readings within target BG of 70-180 mg/dl (74% vs. 73%), daily basal insulin dose (19 vs. 21 units/day), length of stay (median [IQR]: 9 vs. 9 days), or hospital complications (21.3% vs. 21.4%) between treatment groups. There were no differences in the proportion of patients with BG <70 mg/dl (15.6% vs. 23.1%) or <54 mg/dl (1.6% vs. 4.3%) between degludec-100 and glargine-300 groups | ||
| 520 | |a CONCLUSIONS: Treatment with degludec U100 is as effective and safe as glargine U300 for the early postoperative hospital management of patients with T2D undergoing CABG | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a continuous glucose monitoring system | |
| 650 | 4 | |a degludec U100 | |
| 650 | 4 | |a glargine U300 | |
| 650 | 4 | |a hospital care | |
| 650 | 4 | |a hypoglycemia | |
| 650 | 4 | |a inpatient management | |
| 650 | 7 | |a Insulin Glargine |2 NLM | |
| 650 | 7 | |a 2ZM8CX04RZ |2 NLM | |
| 650 | 7 | |a insulin degludec |2 NLM | |
| 650 | 7 | |a 54Q18076QB |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 700 | 1 | |a Mathew, Anu |e verfasserin |4 aut | |
| 700 | 1 | |a Mishra, Mitali |e verfasserin |4 aut | |
| 700 | 1 | |a Surendran, Parvathi |e verfasserin |4 aut | |
| 700 | 1 | |a Kaur, Parjeet |e verfasserin |4 aut | |
| 700 | 1 | |a Wasir, Jasjeet Singh |e verfasserin |4 aut | |
| 700 | 1 | |a Gill, Harmandeep Kaur |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Rujul |e verfasserin |4 aut | |
| 700 | 1 | |a Gagneja, Sakshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kohli, Chhavi |e verfasserin |4 aut | |
| 700 | 1 | |a Kumari, Poonam |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Manish Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Mishra, Sunil Kumar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetic medicine : a journal of the British Diabetic Association |d 1993 |g 40(2023), 1 vom: 30. Jan., Seite e15002 |w (DE-627)NLM012664030 |x 1464-5491 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2023 |g number:1 |g day:30 |g month:01 |g pages:e15002 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/dme.15002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2023 |e 1 |b 30 |c 01 |h e15002 | ||